IKT Stock Analysis: Buy, Sell, or Hold?
IKT - Inhibikase Therapeutics, Inc. Common Stock
$1.99
0.05 (2.58%)
▲
5d:
+6.42%
30d:
+17.06%
90d:
+9.94%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When IKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: IKT is 7.6% above its trading range ($1.85). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: IKT is 7.6% above its trading range ($1.85). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: IKT is currently trading at $1.99, which is considered extended relative to its 30-day fair value range of $1.64 to $1.85.
Technical Outlook: Technically, IKT is showing sideways momentum. The price is approaching resistance at $1.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IKT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.88 (+195.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IKT is showing sideways momentum. The price is approaching resistance at $1.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IKT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.88 (+195.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.64 -
$1.85
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range (+7.6% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 195.2% below Wall St target ($5.88)
Trading Range Analysis
30-Day Trading Range
$1.64 -
$1.85
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.61
Resistance Level
$1.79
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.24
Wall Street Target
$5.88
(+195.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 02, 2026 9:42 PM ET
Data refreshes hourly during market hours. Next update: 10:42 PM
Data refreshes hourly during market hours. Next update: 10:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
